Blood and lung clues may predict biologic success in severe ACOS

NCT ID NCT07602881

Not yet recruiting Knowledge-focused Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Source: ClinicalTrials.gov ↗

First seen May 24, 2026 · Last updated May 24, 2026

Summary

This study aims to find markers in blood and lung scans that can predict how well patients with severe eosinophilic ACOS (a mix of asthma and COPD) will respond to biologic drugs like benralizumab, mepolizumab, or dupilumab. Researchers will follow 500 adults for 48 weeks after starting treatment, collecting blood samples and imaging data. The goal is to build a model that helps doctors choose the right biologic for each patient, improving outcomes and reducing trial-and-error.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEVERE EOSINOPHILIC ACOS (ASTHMA-COPD OVERLAP) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Union hospital, Tongji Medical college, Huazhong University of Science and Technology

Wuhan, Hubei, 430022, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

SEVERE EOSINOPHILIC ACOS (ASTHMA-COPD OVERLAP)